Thoralf Lange, Thomas Ernst, Franz X. Gruber, Jacqueline Maier, Michael Cross, Martin C. Müller, Dietger Niederwieser, Andreas Hochhaus, Markus Pfirrmann. The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. haematol [Internet]. 2013Apr.30 [cited 2024Apr.25];98(5):714-7. Available from: https://haematologica.org/article/view/6658